Predicting outcomes for older adults undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy is critical. Frailty is associated with poor outcomes, but can be difficult to measure in clinical practice. We retrospectively analyzed patients age ≥65 years receiving commercial CAR-T at Mass General Brigham for multiple...
J. Enns, M. Korst, Nora K. Horick et al.· Blood Advances· 0 citations
In this pilot, SHIFT was endorsed as highly valuable and demonstrated significant, scalable impact up to 6 weeks post-course, which could align current fellowship training with guideline-informed best practice, with major potential benefits for patient care and health outcomes.
J. B. Reese, Ann S. LaCasce, K. Sorice et al.· JCO Oncology Practice· 0 citations
BACKGROUND
Induction chemotherapy has long been a key component of curative therapy for fit patients with acute myeloid leukemia (AML), despite its frequently severe side effects and substantial health care utilization. For patients who are ineligible for induction chemotherapy, hypomethylating therapy plus venetoclax...
Amir T. Fathi, Alexander E. Perl, Geoffrey Fell et al.· New England Journal of Medic...· 3 citations
546
Background:
Chimeric antigen receptor T-cell therapy (CAR-T) has transformed treatment for hematologic malignancies. Frailty is broadly associated with poor outcomes in older adults, but the relationship of frailty with healthcare utilization in patients receiving CAR-T remains incompletely characterized....
M. Korst, J. Enns, Nora K. Horick et al.· JCO Oncology Practice· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
